BioNTech stock is a "Strong Buy", driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. Read ...

A rapid, two-step immune reaction may underlie rare cases of heart inflammation seen after Covid mRNA vaccination, Stanford ...

BioNTech SE (NASDAQ:BNTX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Clear ...

BioNTech's latest narrative update reflects a slightly higher fair value estimate of about $138, tempered by a modestly increased discount rate of roughly 6.72%, as analysts balance confidence in the ...

A closer look at phase 3 data on BioNTech and OncoC4’s anti-CTLA-4 antibody has shown the efficacy that excited analysts last ...

BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative ...

Global interim Phase 2 data in locally advanced/metastatic triple-negative breast cancer (”TNBC”) show encouraging antitumor activity for ...

BioNTech SE ( ($BNTX) ) has issued an announcement. On December 9, 2025, BioNTech SE and Bristol Myers Squibb announced interim results from a ...

BioNTech SE ( ($BNTX) ) has provided an update. On December 6, 2025, BioNTech SE and OncoC4, Inc. presented promising data from the non-pivotal ...

Selective Treg modulator gotistobart (BNT316/ONC-392) showed a reduction in the risk of death by more than half compared to standard of care ...

German biotech BioNTech USA-based OncoC4 yesterday presented data from the non-pivotal dose-confirmation stage of the global ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.